Summary
Acetyl-levo-carnitine (ALC) protects against 1-methyl, 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced toxicity in the nonhuman primate. ALC pretreated monkeys do not show signs of parkinsonism or electroretinographic changes typical of dopaminergic deficiency when given MPTP. In addition, pilot neurochemical and morphological data confirm a partial protection effect. While MAO-B inhibitors, like L-Deprenyl, are thought to protect dopaminergic neurons from MPTP-induced cell death by preventing the conversion of MPTP to its toxic metabolite MPP+, ALC is not known to have MAO-B affnity. Converging evidence suggests that ALC may affect directly mitochondrial respiration, which is known to be the target of MPP+ and affected in human neurodegenerative diseases, including Parkinson's disease. The results of this study point to new therapeutic avenues for the treatment of these nosologic entities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bahl JJ, Bressler R (1987) The pharmacology of carnitine. Ann Rev Pharmacol Toxicol 27: 257–277
Bodis-Wollner I (1990a) Physiological effects of acetyl-levo-carnitine in the central nervous system. Int J Clin Pharmacol Res 10: 109–114
Bodis-Wollner I (1990b) Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 13: 296–302
Bremer J (1983) Carnitine-metabolism and functions. Physiol Rev 63: 1420–1480
Burlina AP, Sershen H, Debler EA, Lajtha A (1989) Uptake of acetylcarnitine in the brain. Neurochem Res 14: 489–493
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550
Cohen G, Pasik A, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur J Pharmacol 106: 209–210
Di Lisa F, Toninello A, Bobyleva-Guarriero V, Morbiato S, Siliprandi N (1986) Protective action of L-carnitine on mitochondrial energy linked processes impaired by aging. In: Van Bezooijen CFA, Miglio F, Knook DL (eds) Liver drugs and aging. Eurage, Rijswijg, pp 103–110
Falchetto S, Kato G, Provini L (1971) The action of carnitines on cortical neurons. Can J Physiol Pharmacol 49 (1): 1–7
Fritz IB (1963) Carnitine and its role in fatty acid metabolism. Adv Lipid Res 1: 285–334
Ghilardi MF, Bodis-Wollner I, Onofrj MC, Marx MS, Glover A (1988a) Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 111: 131–149
Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M (1988b) Systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 43: 255–262
Ghilardi MF, Marx MS, Bodis-Wollner I, Camras CB, Glover AA (1989) The effect of intraocular 6-hydroxydopamine on retinal processing of primates. Ann Neurol 25: 357–364
Harnois C, Marcotte G, Bedard PJ (1987) Alteration of monkey retinal oscillatory potentials after MPTP injection. Doc Ophthalmol 67: 363–369
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469
Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridium ion (MPP+) after their stereotaxic administration to rats. Neurosci Lett 62: 389–394
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonian-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177
Javitch JA, Snyder SH (1984) Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonian-inducing neurotoxin MPTP. Eur J Pharmacol 106: 455–456
Mizuno Y, Suzuki K, Sone N, Saitoh T (1988) Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci Lett 91: 349–353
Mytilineou C, Cohen G (1984) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science 225: 529–553
Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503–2508
Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE (1987) Molecular mechanisms of MPTP-induced toxicity. IV. MPTP, MPP+ and mitochondrial function. Life Sci 40: 721–729
Nguyen-Legros J, Savy C (1988) Dopamine innervation of the vertebrate retina: morphological studies. In: Bodis-Wollner I, Piccolino M (eds) Dopaminergic mechanisms of vision. Alan R Liss, New York, pp 1–17
Onofrj MC, Ghilardi MF, Bodis-Wollner I, Glover A (1986) L-Acetylcarnitine (LAC) prevents MPTP-induced parkinsonian like syndrome (PS) in the monkey. Neurology 36 [Suppl 1]: 96
Parker WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719–723
Pasik P, Pasik T, Pecci Saavedra JP (1982) Immunocytochemical localization of serotonin at the ultrastructural level. J Histochem Cytochem 30: 760–764
Qu ZX, Neff NH, Hadjiconstantinou M (1988) MPP+ depletes retinal dopamine and induces D-1 receptor supersensitivity. Eur J Pharmacol 148: 453–455
Ramsay RR, Salach JI, Dadgar J, Singer TP (1986) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Comm 135: 269–275
Reinhard JF Jr, Diliberto EJ Jr, Viveros OH, Daniels AJ (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84: 8160–8164
Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823–827
Siliprandi N, Siliprandi D, Ciman M (1965) Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem J 96: 777–780
Snyder JW, Kyle ME, Ferraro TN (1990) L-carnitine delays the killing of cultured hepatocytes by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Arch Biochem Biophys 276: 132–138
Villa RF, Gorini A, Zanada F, Benzi G (1986) Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus. Arch Int Pharmacodyn Ther 279: 195–211
Villa L, Turpeenoja L, Benzi G, Stella AMG (1988) Action of L-acetylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum. Neurochem Res 13: 909–916
Westlund KN, Denney RM, Kochenperger LM, Rose RM, Abell CW (1985) Distinct monoamino oxidase A and B populations in primate brains. Science 230: 181–183
Wong C, Ishibashi T, Tucker G, Hamasaki D (1985) Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of parkinsonism. Exp Eye Res 40: 509–519
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bodis-Wollner, I., Chung, E., Ghilardi, M.F. et al. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm Gen Sect 3, 63–72 (1991). https://doi.org/10.1007/BF02251137
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02251137